Skip to main content
OpenTrials
Completed

NCT Number: NCT04422561

Prophylactic Ivermectin in COVID-19 Contacts

asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms & diagnosis of COVID -19

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID

Age range

16 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Zagazig University

Zagazig, Sharqia Province, 44519, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

family contact of confirmed COVID-19 case

Exclusion criteria

  • refuse to participate and receive the drug pregnancy or lactation known hypersensitivity to ivermectin

Treatment and study plan

Ivermectin Tablets

Drug

two doses 72 hours apart

Primary outcomes

  1. Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)

    Time frame: within 14 days after enrollement

    history taking and clinical examination

Secondary outcomes

  1. Development of COVID

    Time frame: within 14 days after enrollement

    by swab

Sponsors and collaborators

Lead sponsor

Zagazig University

Other Gov

Registry information

Official study title

Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jun 9, 2020
Registry last updated
Aug 27, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.